Will itrm go up today

Iterum Therapeutics (ITRM) is not likely to experience a significant increase in its stock price today. Here's why:

1. Recent Performance: ITRM's stock has shown a decline, with a 4.63% drop on September 10, 2024. This indicates a bearish trend in the short term.

2. Technical Indicators: The MACD is at -0.04, which typically indicates a bearish trend. The RSI is at 38.31, suggesting the stock is neither overbought nor oversold. The KDJ is at 20.3, which could be interpreted as an oversold condition, but it doesn't necessarily point to an immediate upward movement.

3. Market Sentiment: The recent FDA Advisory Committee discussion did not result in a vote on sulopenem etzadroxil/probenecid, but it acknowledged oral sulopenem as an important treatment option. This could be positive for the stock in the long term, but it doesn't guarantee an immediate price increase.
4. Analyst Ratings: Despite the bearish technical indicators, H.C. Wainwright analyst Ed Arce has reiterated a Buy rating and a $5.00 price target, which may provide some support to the stock.

In conclusion, while there is some positive sentiment from the FDA discussion and the analyst rating, the technical indicators and recent price movement suggest that Iterum Therapeutics is not poised for a significant increase today. Investors should consider these factors and their own risk tolerance before making investment decisions.